The Role of PET-CT Imaging in Prostate Cancer

Manil Subesinghe; Meghana Kulkarni; Gary J. Cook

doi:10.1053/j.sult.2020.04.004

The Role of PET-CT Imaging in Prostate Cancer

Manil Subesinghe^*, Meghana Kulkarni, Gary J. Cook

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

2 Citations (Scopus)

164 Downloads (Pure)

Abstract

Prostate cancer is the commonest malignancy to affect men in the United Kingdom. Extraprostatic disease detection at staging and in the setting of biochemical recurrence is essential in determining treatment strategy. Conventional imaging including computed tomography and bone scintigraphy are limited in their ability to detect sites of loco-regional nodal and metastatic bone disease, particularly at clinically relevant low prostate-specific antigen levels. The use of positron emission tomography-computed tomography has helped overcome these deficiencies and is leading a paradigm shift in the management of prostate cancer using a wide range of radiopharmaceuticals. Their mechanisms of action, utility in both staging and biochemical recurrence, and comparative strengths and weaknesses will be covered in this article.

Original language	English
Pages (from-to)	373-391
Number of pages	19
Journal	Seminars in Ultrasound, CT and MRI
Volume	41
Issue number	4
Early online date	17 May 2020
DOIs	https://doi.org/10.1053/j.sult.2020.04.004
Publication status	Published - Aug 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1053/j.sult.2020.04.004

The role of PET-CT_SUBASINGHE_Accepted2020_ePublished17May2020_GREEN AAMAccepted author manuscript, 353 KBLicence: CC BY-NC-ND

Cite this

@article{b4a58628dec04b7c8b2f3e56bcf9510a,

title = "The Role of PET-CT Imaging in Prostate Cancer",

abstract = "Prostate cancer is the commonest malignancy to affect men in the United Kingdom. Extraprostatic disease detection at staging and in the setting of biochemical recurrence is essential in determining treatment strategy. Conventional imaging including computed tomography and bone scintigraphy are limited in their ability to detect sites of loco-regional nodal and metastatic bone disease, particularly at clinically relevant low prostate-specific antigen levels. The use of positron emission tomography-computed tomography has helped overcome these deficiencies and is leading a paradigm shift in the management of prostate cancer using a wide range of radiopharmaceuticals. Their mechanisms of action, utility in both staging and biochemical recurrence, and comparative strengths and weaknesses will be covered in this article.",

author = "Manil Subesinghe and Meghana Kulkarni and Cook, {Gary J.}",

year = "2020",

month = aug,

doi = "10.1053/j.sult.2020.04.004",

language = "English",

volume = "41",

pages = "373--391",

journal = "Seminars in Ultrasound, CT and MRI",

issn = "0887-2171",

publisher = "W.B. Saunders Ltd",

number = "4",

}

TY - JOUR

T1 - The Role of PET-CT Imaging in Prostate Cancer

AU - Subesinghe, Manil

AU - Kulkarni, Meghana

AU - Cook, Gary J.

PY - 2020/8

Y1 - 2020/8

N2 - Prostate cancer is the commonest malignancy to affect men in the United Kingdom. Extraprostatic disease detection at staging and in the setting of biochemical recurrence is essential in determining treatment strategy. Conventional imaging including computed tomography and bone scintigraphy are limited in their ability to detect sites of loco-regional nodal and metastatic bone disease, particularly at clinically relevant low prostate-specific antigen levels. The use of positron emission tomography-computed tomography has helped overcome these deficiencies and is leading a paradigm shift in the management of prostate cancer using a wide range of radiopharmaceuticals. Their mechanisms of action, utility in both staging and biochemical recurrence, and comparative strengths and weaknesses will be covered in this article.

AB - Prostate cancer is the commonest malignancy to affect men in the United Kingdom. Extraprostatic disease detection at staging and in the setting of biochemical recurrence is essential in determining treatment strategy. Conventional imaging including computed tomography and bone scintigraphy are limited in their ability to detect sites of loco-regional nodal and metastatic bone disease, particularly at clinically relevant low prostate-specific antigen levels. The use of positron emission tomography-computed tomography has helped overcome these deficiencies and is leading a paradigm shift in the management of prostate cancer using a wide range of radiopharmaceuticals. Their mechanisms of action, utility in both staging and biochemical recurrence, and comparative strengths and weaknesses will be covered in this article.

U2 - 10.1053/j.sult.2020.04.004

DO - 10.1053/j.sult.2020.04.004

M3 - Article

AN - SCOPUS:85085204964

SN - 0887-2171

VL - 41

SP - 373

EP - 391

JO - Seminars in Ultrasound, CT and MRI

JF - Seminars in Ultrasound, CT and MRI

IS - 4

ER -

The Role of PET-CT Imaging in Prostate Cancer

Abstract

UN SDGs

Access to Document

Fingerprint

Cite this